ASCVD Risk and Statin Use in PADatherosclerosiscardiovascular diseasecardiovascular eventshydroxymethylglutaryl-CoA reductase inhibitorsperipheral artery diseasesecondary preventiondoi:10.1016/j.jacc.2020.06.009Marc P. BonacaConnie N. HessJournal of the American College of Cardiology...
参考文献: [1] Mahmoud A, Almohtasib Y, Naeem A, et al. Abstract 4138221: Ezetimibe plus statin combination vs. double dose statin for patients with dyslipidemia and ASCVD risk: A Systematic Review and Meta-Analysis [...
参考文献: [1] Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials[J].Lancet, 2010,375:735-742. [2] Choi JY, Choi CU , Hwang SY et al. Effect of Pitavastatin Compared with Atorvastatin and Rosuvastatin ...
42. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including...
[2] Bonaca MP, Hess CN. ASCVD Risk and Statin Use in PAD: Implementing a new approach to an old problem. J Am Coll Cardiol. 2020;76:265-267.
[13]. George Thanassoulis, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014 Apr 14;3(2):e000759. ...
1. Özcan C, et al.Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):25-35.
[11] Sabatine MS et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol...
4. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial[J]. Eur Heart J, 2020, 41(40): 3925-3932. ...
For example, liver function tests and kidney function tests help pharmacists determine which statin is most appropriate. In the community pharmacy setting, access to labs and lab data is difficult, meaning all patients with borderline risk or greater had to be referred to their primary care ...